capture the important and codependent relationship between virus and host, which is exemplified by the immune escape of viruses from human leukocyte antigen-determined immunodominant epitopes, which lead to fixing of such mutants within genetically related populations [3] .
Clinical studies have addressed differences in disease progression between viral subtype and outcome, although results are inconclusive, if not contradictive. The most consistent findings have been that subtype D is associated with faster disease progression, at least when compared with subtype A. Limited data exist on the comparison of B with non-B subtypes [5] [6] [7] [8] [9] [10] , mostly from crosssectional studies or individuals with unknown HIV infection duration. These studies also have small numbers short follow-up periods, which necessitates broad comparisons between one subtype and all the other subtypes grouped together.
In Western European countries, the epidemic was initially dominated by subtype B [1, 2] , which is one of the reasons why studies on the effect of HIV-1 subtypes on disease progression are rare in this geographical area. However, extensive patterns of migration have now introduced a wide range of other subtypes [11] [12] [13] [14] , offering an opportunity of studying the impact of virus determinants across a range of host genetic backgrounds within similar healthcare systems.
The objective of this study was to investigate the association between HIV-1 subtypes and disease progression as expressed by temporal trends in CD4 lymphocyte cell counts, viral load (VL) set point, and time from seroconversion to AIDS or death.
METHODS

Study Population
We used CASCADE (Concerted Action of Seroconversion to AIDS and Death in Europe) data, a collaboration of 28 seroconverter cohorts [15] , pooled in September 2011 within the European Coordinating Committee for the Integration of Ongoing Coordination Actions Related to Clinical and Epidemiological HIV Research (EuroCoord; www.EuroCoord.net). All collaborating cohorts received approval from their respective regulatory or national ethics review boards (see Appendix).
For the majority (84.6%), seroconversion dates were estimated as the midpoint between the last documented negative and first positive HIV antibody test dates with an interval of 3 years or less between tests. For the remainder, seroconversion date was estimated through laboratory evidence of acute seroconversion ( polymerase chain reaction positivity in the absence of HIV antibodies, or antigen positivity with fewer than 4 bands on Western blot), or as the date of seroconversion illness with both an earlier documented negative and a later positive HIV test not more than 3 years apart.
Individuals followed up in 2 African cohorts in CASCADE, infected almost exclusively with non-B HIV-1 subtypes, were excluded from current analyses, as they may differ from those living in high-income countries in various environmental and host factors, making an independent assessment of the effect of subtype difficult, if not impossible. We also excluded individuals who seroconverted prior to 1996, as the proportion of individuals infected with non-B HIV-1 subtypes was particularly low (3.4% vs 31% for those seroconverting since 1996). Additionally, combination antiretroviral therapy (cART) that substantially influenced HIV-1 natural history was introduced in 1996. Eligible individuals were aged ≥15 years at seroconversion and had at least 1 CD4 lymphocyte cell count measurement available before initiating any ART or progressing to clinical AIDS. We excluded AIDS-free individuals who received ART during the first year after seroconversion with all prior CD4 measurements >350 cells/μL, as they were likely to have been treated on the basis of being acutely infected.
VL set point was defined as the mean log 10 HIV RNA level over the period 6-24 months following seroconversion in order to avoid high viremia during acute infection and allow for a realistic time for a follow-up appointment after acute infection.
Laboratory Methods
Sequencing was performed by investigators in the country of origin, using various genotypic resistance assays. HIV-1 subtype was derived from nucleotide sequence data spanning the entire protease gene and at least codons 41-236 of reverse transcriptase using the Rega algorithm [16] . HIV RNA and CD4 lymphocyte cell count values were also determined locally. All labs were accredited with ongoing quality assurance programs.
Statistical Analysis
We estimated the mean CD4 lymphocyte cell count trends over time, accounting for the correlation among repeated measurements within each individual, through linear mixed models with random intercept and random slope [17] . We used the square root transformation of CD4 values to normalize distribution, stabilize variance, and linearize changes over time. Log 10 -transformed VL set point levels were modeled through median regression. CD4 lymphocyte cell count and HIV RNA measurements taken after any ART initiation or clinical AIDS onset were excluded from all analyses.
AIDS and death rates, overall and by subtype, were estimated and compared using survival analysis techniques (log-rank tests and Cox models), adjusting for delayed entry into the cohorts. For the analysis of time to AIDS/death, the whole available follow-up time was considered (ie, without censoring at ART initiation).
Multivariable models were adjusted for gender, risk and ethnic group, age at and year of SC, time interval between SC and enrolment into a CASCADE cohort, and evidence of acute infection. Sensitivity analyses were undertaken to allow for potential residual confounding of ethnicity and risk group by restricting models to whites and individuals infected through sex between men and women (MSW), respectively. Also, to investigate the robustness of our main findings, taking into account the potentially informative truncation [18] of CD4 lymphocyte cell count measurements due to cART initiation, our final multivariable mixed model was refitted using joint models for both the evolution of CD4 lymphocyte cell counts and the time to the potentially informative event (ART initiation). Furthermore, we repeated the analysis censoring follow-up at 3 years following seroconversion to minimize potential bias resulting from censoring mechanisms.
All analyses were performed using Stata 10.1 (StataCorp). Joint models were fitted through the joint multivariate random effects ( JMRE) [18] method using the user-written jmre1 command in Stata [19] .
RESULTS
Study Population Characteristics
Of 25 629 individuals in CASCADE, 13 470 were excluded (5 unknown AIDS diagnoses dates, 885 from African cohorts, 9954 seroconverted before 1996, two aged <15 years, 1465 without ART-naive and AIDS-free CD4 lymphocyte cell count measurements, and 1159 who started treatment within the first year of seroconversion while AIDS-free and with CD4 >350 cells/μL). Of 12 159 individuals remaining, HIV-1 subtype was known for 3364 (27.7%).
Individuals with known subtypes were, on average, more likely to be white, of non-African origin, and infected through sex between men (MSM). They also had shorter delays between seroconversion and cohort enrolment and were more likely to have an acute infection (ie, HIV test interval ≤30 days, laboratory evidence of seroconversion, or presence of seroconversion illness).
Among the 3364 with known HIV-1 subtype, the predominant subtype was B for 2796 (83.1%), followed by CRF02 for 194 (5.8%), C for 92 (2.7%), CRF01 for 76 (2.3%), A for 69 (2.1%), other recombinants (46 with various other CRFs and 19 with unique recombinant forms) for 65 (1.9%), G for 37 (1.1%), and other subtypes (19 D, 16 F) for 35 (1.0%) individuals. As our main aim was to investigate the effect of each single subtype, we excluded data from individuals with subtypes infecting <30 individuals (n = 100).
The demographic and clinical characteristics of the remaining 3264 individuals, according to HIV-1 subtype, are shown in Table 1 . Individuals with non-B subtypes were more likely to be black, infected through MSW, slightly older, and more recently infected. The vast majority of individuals infected through injecting drug use (86.8%) and MSM (94.1%) were infected with subtype B, whereas half of MSW were infected with non-B subtypes (48.9%). Time between seroconversion and cohort enrollment did not differ by HIV-1 subtype with the overall median (interquartile range [IQR]) being 2 (0-6) months. However, follow-up time, either censored at ART initiation or at clinical AIDS onset, was longer for those infected with CRF01 subtype and shorter for those infected with G subtype. Frequency of CD4 lymphocyte cell count and HIV RNA measurements was similar across all groups subtypes (data not shown).
CD4 Lymphocyte Cell Count Evolution
After adjusting for the potential effect of other variables, compared with subtype B, we estimated lower CD4 lymphocyte cell count at seroconversion for individuals infected with subtype C, and higher for CRF01. Compared with subtype B, the rate of CD4 cell loss was significantly slower for individuals infected with subtypes A and CRF02, and marginally slower for subtype C ( Table 2) .
White individuals had higher initial CD4 lymphocyte cell count levels, but their rate of subsequent loss was higher compared with other ethnic groups. Likewise, compared with men, women had higher initial CD4 lymphocyte cell counts but steeper CD4 declines. As expected, older age at seroconversion was associated with faster CD4 cell loss. Individuals with acute infection had lower initial CD4 lymphocyte cell counts but slower subsequent decline compared with those without acute infection. Notably, compared with those infected during 1996-1999, those infected in later calendar periods had steeper CD4 declines, although we found no evidence of a continuing increase in rate of decline by year of seroconversion.
As an illustration of subtype differences, the estimated mean (95% confidence interval [CI]) CD4 at seroconversion, at 2 and 4 years, and estimated loss in the first 2 and 4 years are given in Table 3 for white MSM, aged 30-39 years at seroconversion, without acute infection, who seroconverted since 2006. Predicted average CD4 lymphocyte cell count evolution by HIV subtype for the same group is shown in Figure 1A .
Restricting the analysis to white or MSW individuals yielded estimates of the subtype effects consistent with those of the main analysis. Adjustment for potentially informative truncation of CD4 lymphocyte cell count measurements due to cART initiation, through a joint model, resulted in a much faster estimated decline in CD4 lymphocyte cell count, but the average CD4 levels at seroconversion and the corresponding differences between subtypes remained consistent with those of the main analysis. Artificially censoring follow-up at 3 years after seroconversion and applying the main multivariable model resulted in negligible changes in the estimated coefficients.
Viral Load Set Point
Of the 3264 study population, 2526 (77.4%) had at least 1 HIV RNA measurement available within 6-24 months after seroconversion. Box plots of log 10 -transformed VL set point levels are presented in Figure 1B . Levels differed significantly by subtype (Kruskal-Wallis; P = .004), being highest for those infected with subtype B at a median (IQR) of 4.50 (3.97-4.93) log 10 copies/mL compared with 4.27 (3.83-4.78), 4.26 (3.69-4.93), 4.31 (3.58-4.74), 4.29 (3.75-4.82), and 4.21 (3.68-4.93) log 10 copies/mL for individuals infected with subtypes A, C, CRF01, CRF02, and G, respectively. The distribution of VL set point levels was not normal, with some groups (mainly subtypes B or C) having a disproportionately large fraction of patients with high viremia (ie, >100 000 copies/mL; Figure 1B ). However, set point levels did not differ significantly by subtype in a multivariable median regression model (Table 4) , although there was a tendency for all subtypes to have lower levels compared with subtype B, except for subtype C, which had the highest levels. Men, increasing age at seroconversion, and white individuals were associated with significantly higher VL set points. Those seroconverting in later years were also more likely to have higher set point levels. death was lower in all non-B subtypes, but the overall difference was not significant (long-rank P = .50), probably due to a small number of events among those infected with non-B subtypes. Comparing jointly all non-B subtypes with subtype B, the adjusted hazard ratio was 0.61, marginally significant (P = .06). Censoring data at ART initiation gave qualitatively similar results to the main analysis.
Clinical Outcomes
DISCUSSION
The size of the CASCADE dataset of HIV-1 infected individuals with well-estimated dates of seroconversion enabled us to compare CD4 lymphocyte cell count evolution and HIV set point in ART-naive individuals infected with subtypes A, B, C, G, CRF01, and CRF02. Overall, we found that rates of CD4 decline were significantly slower for A and CRF02 and marginally slower for C compared with B subtype. We found no evidence, however, to suggest that VL set point levels significantly varied by subtype in adjusted analysis, although there was a tendency for all subtypes, except C, to have lower levels compared with subtype B. There was also no evidence to suggest that the risk of clinical AIDS or death differed by subtype, but the small number of events observed for any one subtype precluded statistical significance. This suggests that the relationship between immunological damage and viral replication may differ between viral subtypes. Such observations inform the use of surrogates for vaccine studies, as well as predictions of outcome across the global epidemic. This study is among the first of large investigations to directly compare rates of CD4 lymphocyte cell count declines and VL set point of non-B subtypes to subtype B. In most previous studies, conducted in low-income countries, the comparator subtype tended to be A, understandably [5, 7, 9, 10] . The most consistent result was that subtype D is associated with faster time to AIDS and/or death, at least compared to A. Subtype D has also been associated with faster rates of CD4 decline compared with subtype A [20] [21] [22] . Unfortunately, the small number of individuals (n = 19) with subtype D in our study did not allow us to investigate this particular subtype. It is of interest, however, that subtypes B and D share a common genetic ancestry, and we may, therefore, expect them to exhibit similar rates of disease progression [23] . Therefore, our results of a significantly slower rate of CD4 lymphocyte cell loss for subtype A (at least when compared with subtype B) may be regarded as being compatible with findings from the African studies.
Our results do not support the hypothesis that recombinants could be more virulent than parent isolates [1, 2, 24] , at Estimates are given for a white man having sex with a man, aged 30-39 years at seroconversion, enrolled into a cohort within 6 months of seroconversion, without acute infection, and who seroconverted since 2006.
Abbreviation: HIV, human immunodeficiency virus. least regarding CRF01 and CRF02. Two studies comparing patients infected with CRF02 and non-CRF02 subtypes reported no difference between the 2 groups in terms of survival, clinical disease progression, or CD4 lymphocyte cell count decline [8, 9] . The main limitation of both studies, however, is that all non-CRF02 subtypes were grouped together, although the majority of those with non-CRF02 subtypes were, in fact, subtype A (46.6% and 60%, respectively). In our study, although individuals with CRF02 subtype had slower CD4 lymphocyte cell count declines compared with those infected with subtype B, no significant differences were observed between the other non-B subtypes, with the exception of subtype G. In that sense, our results are compatible with those 2 studies. Other studies have reported findings which contradict our own, although findings are not directly comparable, as the comparator subtype was not subtype B in those studies. Kiwanuka et al [21, 25] have reported higher rates of progression to death and faster CD4 lymphocyte cell count declines in those infected with recombinant or multiple subtypes compared with those with A subtype, whereas Tek et al [26] found increased rates of CD4 lymphocyte cell count decline in subtype CRF01-infected patients compared with non-CRF01 patients. Mori et al [27] , on the other hand, found that a substantial number of unique cytotoxic T-lymphocyte epitopes exist in CRF01 infection, which are associated with lower viral load and delayed disease progression, a finding that favors our results. Results about subtype C and disease progression in naive patients remain inconclusive. In vitro studies suggest that subtype C is less replicatively competent than subtype B [1, 2, 4] . It should be noted, however, that subtype C dominates the worldwide epidemic, which may reflect increased infectivity/ transmissibility [1, 2] . In our study, we found that those infected with subtype C had marginally significant slower CD4 declines but similar VL set point compared with those infected with subtype B. Novitsky et al [28] reported high rates of individuals maintaining high HIV RNA levels after acute infection for subtype C infection. If this finding is confirmed in other studies, it could have serious clinical implications, as high viremia is associated with increased transmission efficacy [29] .
African descent has been shown to be associated with lower CD4 lymphocyte cell counts at seroconversion and slower CD4 declines in HIV-1-infected treatment-naive patients [30, 31] . These findings were also confirmed in our study. We also found that African origin is associated with lower set point viremia. HIV-1 subtypes tend to cluster within specific ethnic and HIV risk groups. Thus, these factors are potentially important confounders. In all analyses, we controlled for both ethnic and HIV risk group. Additionally, we used a set of sensitivity analyses to allow for potential residual confounding by restricting analyses to white individuals, and to MSW. In both cases, results were compatible with those of the main analyses. This is among the largest seroincident studies to address the effect of HIV-1 subtype on disease progression in terms of CD4 lymphocyte cell count rates of decline and VL set point in treatment-naive individuals, and also novel in its direct comparison of B with non-B subtypes. Despite this, we were not able to study the whole spectrum of HIV-1 subtypes due to the small number of seroconverters included in CASCADE who were infected by some subtypes. Nonetheless, our study included data from sufficient numbers to allow us to compare rates of CD4 lymphocyte cell count decline and VL set point in patients infected with 5 major subtypes/recombinants; namely, A, B, C, CRF01, and CRF02. These results are of clinical importance, as they point out that viral genetic diversity is likely to play a role in a patient's disease progression.
Finally, we recognize that viruses evolve in the context of the host, and that the introduction of specific subtypes into a new population, as is being witnessed in Europe, may lead to different manifestations of infection. Ultimately, the ability of viruses to spread will be defined by the growth dynamics within these new host populations. These studies are being undertaken within the CASCADE collaboration. 
Notes
